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Abstract
Access to "high cost medicines" through Australia's Pharmaceutical Benefits Scheme (PBS) is tightly
regulated. It is inherently difficult to apply any criteria-based system of control in a way that
provides a fair balance between efficient use of limited resources for community needs and
equitable individual access to care. We suggest, in relation to very high cost medicines, that the
present arrangements be re-considered in order to overcome potential inequities. The biological
agents for the treatment of rheumatoid arthritis are used as an example by which to discuss the
ethical issues associated with the current scheme. Consideration of ethical aspects of the PBS and
similar programs is important in order to achieve the fairest outcomes for individual patients, as
well as for the community.
Background
The goal of health care, stated in the Australia's National
Medicines Policy, is to achieve optimal health and eco-
nomic outcomes for society as a whole as well as for the
individual patient [1]. Within the National Medicines Pol-
icy, the Pharmaceutical Benefits Scheme (PBS) aims to
ensure affordable access to a wide range of prescription
medicines equitably across all medical areas for Austral-
ians [2]. How health or pharmaceutical expenditure
should be allocated is a very specific example of the gen-
eral issue of distributive justice [3]. Healthcare payers
world-wide cannot provide every medicine for all citizens
without limitations, particularly for a national health sys-
tem such as that found in Australia, where health services
are heavily subsidised by tax revenues. "High cost medi-
cines" (HCMs), predominantly products of the molecular
biology revolution, have highlighted this dilemma. The
concept of HCMs has not yet been clearly defined interna-
tionally. In Australia, HCMs have been described by Vic-
torian public hospitals as medicines whose acquisition
cost is greater than AUD$10,000 per patient per treatment
course [4]. While HCMs have not been explicitly defined
within the PBS it is important to note that if the total use
of a drug is expected to cost more than AUD$10 million a
year, its subsidy needs approval by the Commonwealth
Department of Finance and Administration, or by the
Cabinet [5]. This requirement would apply to, in relative
terms (i) drugs of low unit cost but high utilization and
(ii) drugs of high unit cost but low utilization. Most bio-
logical medicines are within the latter category.
Although the price of a medicine submitted for PBS sub-
sidy ('listing') is an important issue, its cost-effectiveness
is a more critical question to be answered in the PBS deci-
sion-making process. In an attempt to balance the bene-
fits, risks and costs, PBS-subsidised access to medicines,
including high-cost, biological medicines, is targeted to
patients with the greatest capacity to benefit. The aim is to
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cost per unit of incremental benefit). For medicines that
are of high cost per patient, patients with the greatest
capacity to benefit are likely to be a subset of patients with
more advanced and active disease who have not been ade-
quately controlled using less expensive, generally older
and more established therapies. Provision of HCMs
through the PBS is a significant achievement from the per-
spective of patient care and is concordant with the ethical
principle of fairness. An effect, however, is that complex
requirements for access to HCMs give the funding body an
increased influence over clinical practice.
There has been little consideration of the ethical dimen-
sions of such schemes by which we mean considering the
fairness or equity of the policy and its application. In this
paper, we examine, from an ethical perspective, recent
approaches used in Australia to govern access to HCMs,
using the example of the biological medicines ("biologi-
cals") for the treatment of rheumatoid arthritis (namely,
etanercept, infliximab, adalimumab, and anakinra). The
anti-rheumatic biologicals are expensive (high cost per
patient per year), they exhibit high cost-effectiveness
ratios, their cumulative expenditure is likely to be high
because rheumatoid arthritis is a relatively prevalent
chronic condition, and there are uncertainties regarding
their longer-term safety (such as risks of lymphoma and
rare, serious infections). For these reasons, they provide a
representative illustration of ethical issues associated with
the current scheme.
Discussion
Prioritising access to high-cost medicines: the Australian 
approach
The Pharmaceutical Benefits Advisory Committee (PBAC)
advises the federal Minister for Health about which med-
icines should be subsidised by the PBS. In making its rec-
ommendation, the PBAC considers the clinical and cost
effectiveness of the medicine in relation to alternate ther-
apies from a societal perspective [6]. That is, the PBS
ensures reasonable value-for-money for Australian
patients and taxpayers. Even though the PBS has an
uncapped budget, overall government resources allocated
to health care are limited for the possible range of dis-
eases.
Requirements for access to HCMs (as here defined) under
the PBS, in general, include the presence of 'severe active
disease', 'molecular markers', and specified measures in
follow-up assessment (Table 1) [7]. The criteria are based
primarily on evidence from randomised controlled trials.
In principle, this evidence-based approach to decision-
making enables decision makers, clinicians and patients
to make more informed decisions and to use resources
more effectively [8-11]. However, benefits will not always
extend to all individuals when access to medicines is
rationalised according to 'average' responses observed in
clinical trials. Additionally, patients who are participants
in clinical trials are a small, and often not a closely repre-
sentative, sample of the population of patients affected by
the disease.
Economic evaluation is increasingly used to prioritise pro-
vision of treatments for different medical conditions in
response to burgeoning demands for health care. In gen-
eral, clinicians tend to favour an individual rights-based
view of ethics. By contrast, the goal of economic evalua-
tion is utilitarian and relates to outcomes for the whole
population [3]. Economic evaluations primarily focus on
efficiency, thereby promoting overall welfare for the
majority [3]. Whilst the majority of patients may benefit,
not all individuals will. Economic analyses can override
concerns for the individual patient such that goals of treat-
ment, rational selection of treatments, and the individual
patient's experience and perspective are ignored [12,13].
The limitations of making inferences from population-
based evidence to individual patients, are not only rele-
vant to the PBS approach, but are inherent in the "formu-
lary" decisions of any organisation made on the basis of
evidence from clinical trials and economic evaluations.
Table 1: Common requirements of access to high cost medicines under the PBS [15]
"Authority prescription" requirements
Criteria for initiating treatment • Severe active disease
• Presence of "molecular markers" that predict a good treatment outcome
• Failure to achieve adequate response to a step-up sequence of cheaper existing therapies
• Patients required to sign a 'patient acknowledgement form'
A patient agreement process • A Patient Acknowledgement Form to be signed by patients to acknowledge that treatment will only 
continue if the predetermined response criteria are achieved at follow-up assessment (e.g. 12 weeks for 
biological anti-rheumatic agents)
Criteria for continuing treatment Clinical outcomes are evaluated according to predetermined quantifiable criteria at follow-up assessment
Restricted prescribing rights • Prescription only by specialist physicians (e.g. rheumatologists initially for biologicals for rheumatoid 
arthritis. Prescribing rights were extended to clinical immunologists with expertise in the management of 
rheumatoid arthritis as of February 2004)
Risk sharing arrangement • Price-volume agreement between sponsor and the governmentPage 2 of 7
(page number not for citation purposes)
Australia and New Zealand Health Policy 2008, 5:4 http://www.anzhealthpolicy.com/content/5/1/4Likelihood of success (or capacity to benefit) is a necessary
criterion from the perspective of distributive justice
because a scarce resource should be distributed to patients
who have a reasonable chance of benefit [3]. Targeting
access to those with the greatest likelihood of success (for
whom it represents good value for money) is used as a
rational and equitable approach to deal with the difficult
matter of access to medicines including HCMs under the
PBS. This approach has increasingly relied upon 'molecu-
lar markers' or genetic information for individual
patients. Examples of drugs whose funding by the Austral-
ian government already requires individual genetic infor-
mation include: trastuzumab for the treatment of breast
cancer (HER2 gene testing); imatinib for patients with
chronic myeloid leukaemia (expression of the Philadel-
phia chromosome or the transcript, bcr-abl tyrosine
kinase); and gefitinib for patients with non-small cell lung
cancer (activating mutation of the epidermal growth fac-
tor receptor gene in tumour biopsy) [14,15].
Initially, the surrogate marker, rheumatoid-factor, was a
criterion for access to the biologicals for treating rheuma-
toid arthritis [16], the PBAC having concluded that rheu-
matoid-factor was a 'treatment effect modifier' predictive
of those most severely-affected and with a higher poten-
tial to respond [17]. Additionally, PBAC noted that this
'criterion' had been accepted by the representative rheu-
matologists from the Australian Rheumatology Associa-
tion engaged in the stakeholder consultation process and
by the sponsors [17]. However, this view was based largely
on unpublished data held by the sponsor companies and
was not supported by published literature [18,19]. Conse-
quently, this requirement was subject to intense debate
[17-19]. The rationale for this decision was unknown
because all documents submitted to PBAC are considered
'commercial-in-confidence' by the pharmaceutical indus-
try. The PBAC was not able, therefore, to defend its deci-
sion by tabling the data upon which its decision was
based [17]. As a result, clinicians were unable to explain
or defend this restriction to patients who were excluded
from the treatment because of this criterion. The impor-
tant responsibility of clinicians, who are, in effect, the
'gatekeepers', to manage the expectations of patients as
well as their disease was thus impaired. Additional data
were subsequently provided to the PBAC by the sponsor
[20]. The criterion was removed as of June 2005 as an
acknowledgement that the 'continuation rule' would
cover the issue of 'inadequate' response [21]. The 'contin-
uation rule' requires clear evidence of a substantial
response to justify continued access to HCMs. The PBAC
must be acknowledged for its commitment to address
such problems and its willingness to consider new and
additional data. However, the delay and difficulty in
amending the PBS criteria highlights the issue that lack of
transparency was fundamental to the concerns expressed
by clinicians and patients about this decision. The trans-
parency of PBAC decisions has improved markedly since
then (as is discussed below).
Procedural justice is concerned with making and imple-
menting decisions according to fair processes, that is,
despite the absence of prior agreement on principles, a fair
process yields a just outcome [22]. It requires transpar-
ency and inclusive decision-making processes [22]. These
elements of procedural justice are fundamental to a sense
of community ownership and can offset criticism of the
'economic analysis' based approach to determining access
criteria.
In the context of priority-setting in Australia, the PBAC
bears the final and legislative responsibility for recom-
mending the access criteria for PBS medicines. Neverthe-
less all stakeholders should share in the process of
establishing evidence-based criteria for access. Increas-
ingly, the PBAC interacts with stakeholders to gain input
to and acceptance of its decisions [6]. For example, a
unique stakeholder collaboration between the PBAC,
sponsor companies, and a small group of rheumatologists
(the Australian Rheumatology Association Therapeutics
Committee) contributed to the process for subsidising the
anti-rheumatic biologicals [6,23]. It has been suggested
that more structured and inclusive consultation, and
increased participation by consumer representatives and
patients in future processes would further enhance the
fairness of the process and the system [24,25]. We believe
it would also be valuable if PBS listing decisions and
access criteria were subject to public input through a pub-
licised, formal process of review to accommodate reason-
able arguments or new evidence. Mechanisms for
challenging and disputing decisions are necessary compo-
nents to increase the fairness of the process [22].
Recent moves towards greater transparency of PBAC deci-
sions are welcome developments [6]. An important mile-
stone in this setting is the publication of 'Public Summary
Documents' which have been available on the PBS web-
site since late 2005. These documents now provide an out-
line of submissions (including a list of clinical trials of the
medicine and results of key trials). Although details of the
economic analyses remain unpublished, significant
insights into PBAC decisions are now available through
these documents. They are also useful for informing clini-
cians and patients about safe, effective and cost-effective
use of the new drug in clinical practice.
Transparency also requires disclosure of potential con-
flicts of interest. This is critical for the effectiveness and
acceptance of a trust-based stakeholder engagement proc-
ess. Adequate access to unbiased, credible information
and provision of training and support for stakeholdersPage 3 of 7
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lic) is likely to increase the ability of stakeholders to make
informed contributions as well as to reduce any unbal-
anced influence of the industry on stakeholder perspec-
tives. Furthermore, representatives engaged in the
stakeholder collaboration process have the responsibility
to effectively communicate the rationale behind decisions
to their constituencies. Greater transparency, improved
accountability, and increasing stakeholder involvement
are all necessary in the effort to enhance public under-
standing of, support for, and community ownership of,
PBS decisions. Again, these approaches to improving the
decision-making process around access to medicines can
be considered universal, applying to any organisation
responsible for determining access criteria.
Implementing the PBS restrictions
Three central goals of fairness are equity, efficiency, and
accountability [26]. A basic requirement of justice is that
those with equal needs have equal opportunities to access
care. However, patients with equal needs do not have
equal opportunities to access rheumatological services in
Australia. Access to a rheumatologist varies considerably
between the States and Territories and the PBS criteria
require a rheumatologist to apply for the biologicals on
behalf of the patient. Not surprisingly, analysis of pre-
scription data by geographical location indicates that
there is a correlation between utilisation of biological
agents and the per capita ratio of rheumatologists [27,28].
Patients in remote or rural areas are, therefore, disadvan-
taged. A remedy is needed as the goal of fairness is not
being achieved. Geographical impediments to legitimate
access could be overcome in part, for example, by allow-
ing general physicians in remote and rural areas to apply
for access to HCMs for their patients.
Under the PBS, 'authority required' prescribing restric-
tions are usually employed as part of the access arrange-
ments for HCMs. The 'authority required' mechanism is
designed to limit the publicly funded use of medicines to
those patients whose disease features and previous
responses to therapy identify them as belonging to the
subset of patients in whom the medicine has been shown
to be cost-effective. Medicare Australia, the administering
agency, is an important partner with the PBS in enabling
patients' access to medicines. However, the access proce-
dures to be followed are time-consuming for prescribers
and patients, especially for HCMs where much informa-
tion is requested by Medicare Australia. For example,
there is difficulty locating records of laboratory tests and a
detailed pharmacotherapy history for patients, many of
whom have a long history of disease and have been under
the care of multiple medical practitioners [25]. This prob-
lem is likely to diminish as patients with shorter histories
of rheumatoid arthritis become eligible for these medi-
cines. These requirements, however, are seen to be intru-
sive and a means of 'policing' inappropriate or over-use by
prescribers [25]. The administrative burden is likely to
reduce the amount of time physicians have to interact
with their patients clinically. This issue has also been iden-
tified by pharmaceutical benefit management organisa-
tions in the United States [29]. Such procedures are also
administratively cumbersome and costly for the PBS [25]
thus reducing administrative efficiency.
Due to the significant cost of the biologicals and the
uncertainties regarding their longer-term cost-effective-
ness, it is reasonable to monitor patients closely and with-
draw treatment promptly if it is not effective. This
approach is also good clinical practice for any medicine,
and the 'continuation rule' introduced by the PBS enforces
this. Monitoring whether these indices of good prescrib-
ing practice are occurring at satisfactory rates along with
evaluation of drug utilisation and health outcomes is a
critical aspect of accountability for the PBS. Given the
expenditure and the consequences of commencing or
withholding critical treatments such as the biologicals,
analysis of this data should be considered an ethical
necessity and a wise use of public resources. Increased and
facilitated access to de-identified, individual-level pre-
scription and health outcome data but with appropriate
protections of privacy in place is long overdue in Aus-
tralia. Regular reporting of the outcomes achieved by pro-
grammes of access to HCMs is eminently sensible and
should be considered a high priority [30].
Another innovation in PBS procedures around access to
HCMs in recent years has been the requirement that an
agreement be signed by patients to acknowledge that the
drug treatment will continue only if there is a satisfactory
outcome (or clinical response). However, in the case of
the biologicals, a significant ethical concern has been the
brevity of the written explanation in the Patient Acknowl-
edgement Form. Clearly the patient has a right to be
informed about the criteria that qualify him or her for ini-
tial and on-going access. Provision of explanatory mate-
rial, or guidance to clinicians regarding how to address
this issue with patients, would also be useful. Due to the
complexity of the PBS-criteria, and the costs and potential
risks of toxicity of biologicals, a brief information sheet is
needed to improve understanding of the issues that are
important to a patient seeking subsidised treatment.
The way forward: Appeals on behalf of individual patients
Need and likelihood of success are both value-laden con-
cepts. Individual patient's circumstances need to be con-
sidered in the context of the best available evidence.
Patients near the margins of eligibility for access to a HCM
but not quite meeting all the criteria (that is, evidence of
cost-effectiveness in these sub-sets of patients may bePage 4 of 7
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be examined. Consider a hypothetical scenario of a
patient X with severe active rheumatoid arthritis despite
optimal treatment with the available non-biological med-
icines. The new high-cost biological listed on the PBS is
the next and only option but a criterion for access is not
met – for example, an inflammatory marker – the erythro-
cyte sedimentation rate (ESR) – is lower than the level
specified in the requirements for access (ESR > 25 mm/
hour). The phenomenon of active disease with an unusu-
ally low ESR is well recognised, but such patients are not
admitted to clinical trials because elevated ESR is often an
inclusion criterion for such trials. In our example, patient
X meets all other criteria, thus the drug is very likely to be
as effective as for other patients who meet the criteria,
with the 'continuation rule' governing follow-up clinical
assessment and ongoing access. The argument for denying
access is, therefore, not strong. At an ethical level, we
argue that patients similarly near the criteria limits for eli-
gibility for access to a HCM should be considered individ-
ually. This is because self-funding by most patients is not
a realistic option (e.g., anti-rheumatic biological treat-
ment costs about AUD$20,000 per patient per annum)
and the uncertainty regarding factors that contribute to
success (adequate clinical improvement) of treatment. For
such patients, as in the example above, a formal, fair and
transparent mechanism for appeal would go a long way to
improve the public support for PBS. Similarly, treatment
might be offered to a patient who has a diagnosis that
overlaps considerably with the diagnosis for which access
is allowed. The case to be made would be strong if there
was good published evidence for efficacy in the overlap-
ping condition and again the patient had exhausted all
other evidence-based and reasonable options.
To some extent, pharmacists and medical advisors with
clinical knowledge from Medicare Australia who assess
applications for subsidised treatment have acted as a
"review" panel. This is necessary because any system that
relies on criteria, or the application of rules, needs some
discretion in applying particular rules to the actual cir-
cumstances. In practice there is always some discretionary
function in the application of criteria. We, therefore,
accept that the system for making these judgments and the
current functions within Medicare Australia is a good
starting point. However, we suggest that it is preferable to
establish a process that is open to public scrutiny. A
streamlined appeals panel could be established with a few
clinicians (say three) appointed by the Minister, who
could meet (by telephone) to decide whether a particular
patient should be eligible for subsidised treatment (such
as the cases discussed above). The proposed system would
be applicable to relatively few patients and unlikely to
impose a large administrative burden and cost on the PBS.
This process should be open, fair, consistent and account-
able [22] rather than ad hoc and informal as is the current
situation. Whilst we have suggested the outlines of a for-
mal process, the details of its establishment and imple-
mentation require more thought and public discussion.
Importantly however, the appeal mechanism must reflect
the National Medicines Policy and the integrity of the
PBS. Stakeholder involvement and ownership of the
appeal process so developed will add to its acceptance.
While such a mechanism does introduce a further level of
administration, its cost could be minimal. In any case the
cost is justified by the need for a discretionary function
and the potential for an open process to manage and
reduce the tension between meeting the needs of the pop-
ulation and those of the individuals. We also believe that
such a process could achieve an increase in equity. Even if
the result of an appeal was the rejection of a request for
access, the justification provided to prescribers, patients
and representative groups would improve understanding.
In itself, this would lead to increased acceptance of any
decisions. Risk-sharing agreements (such as price-volume
or rebate agreements) [31] between sponsor and govern-
ment would limit financial exposure of the government
and the taxpayer. These risk sharing instruments are a dis-
incentive to any stakeholders who might be tempted to
abuse the mechanism.
Conclusion
Not everyone who has a rational case for subsidised access
to a particular form of healthcare can gain access to it. This
is because the assessment and establishment of 'cost effec-
tiveness' of particular interventions relies on aggregated
data collected as part of clinical trials, carried out in vary-
ingly representative samples of the wider population
affected by the disease. Some process is needed, therefore,
to overcome these potential inequities and to enhance the
fairness (and perception of fairness) of the system for
accessing HCMs. Wider public debate to determine the
fundamental principles and processes of targeted access to
expensive medicines should, in our view, be a national
priority. Provision of training and support is critical to
achieve greater stakeholder involvement; physicians and
patients are more likely to endorse criteria developed
through an inclusive, transparent decision-making proc-
ess. We advocate a formal mechanism for public input
and review of PBS access criteria when additional, sound
data become available. We also advocate exploring a
defined mechanism to deal with the small number of
individual patients who have exhausted all other treat-
ment options despite PBS access criteria for a HCM not
being met completely. These suggested embellishments to
the PBS, we contend, are critical for ensuring procedural
justice and will increase accountability and public confi-
dence. The PBS in Australia is widely acknowledged to be
outstanding [32,33]. The present proposals are offered toPage 5 of 7
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on some individual patients who are excluded currently
from subsidised access to HCMs when a rational case can
be made to allow access. We believe that the adoption of
these measures would enhance the equity of the Scheme
in respect of patients with a clear and justifiable need and
would ensure that the PBS continues to evolve and func-
tion ethically.
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